2023-01-20
Phase II clinical trial of Immune Onco IMM01 combined with PD-1 monoclonal antibody for relapsed and refractory classical Hodgkin's lymphoma (R/RcHL) completes the first subject to be administered
On January 20, 2023, ImmuneOnco Biomedical Technology (Shanghai) Co., Ltd. (hereinafter referred to as "ImmuneOnco") announced that the first domestic SIRPαFc fusion protein drug targeting human CD47
View more
